Hanmi Science Co Stock

Hanmi Science Co EBIT

The EBIT of Hanmi Science Co (008930.KS) as of Aug 8, 2026 is 37.96 B KRW. In the previous year, EBIT was 57.01 B KRW — a change of -33.42% (lower).

EBIT

37.96 BKRW

YoY

-33.42%

Last updated:

In 2026, Hanmi Science Co's EBIT was 37.96 B KRW, a -33.42% increase from the 57.01 B KRW EBIT recorded in the previous year.

The Hanmi Science Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B KRW)
Date
EBIT (B KRW)
Jan 1, 2017
13.97 base
Jan 1, 2018
11.00 base
Jan 1, 2019
16.15 base
Jan 1, 2020
25.15 base
Jan 1, 2021
28.75 base
Jan 1, 2022
28.11 base
Jan 1, 2023
57.01 base
Jan 1, 2024
37.96 base
YEAREBIT (B KRW)
2024 37.96
2023 57.01
2022 28.11
2021 28.75
2020 25.15
2019 16.15
2018 11.00
2017 13.97
2016 15.07
2015 147.07
2014 9.29
2013 6.82
2012 4.15
2011 3.07
2010 2.73
2009 74.94
2008 81.69
2007 80.81
2006 66.51
2005 58.99
Access this data via the Eulerpool API

Hanmi Science Co Revenue

Hanmi Science Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
652.32 B KRW
13.97 B KRW
30.07 B KRW
Jan 1, 2018
708.00 B KRW
11.00 B KRW
18.02 B KRW
Jan 1, 2019
816.62 B KRW
16.15 B KRW
30.74 B KRW
Jan 1, 2020
857.38 B KRW
25.15 B KRW
22.60 B KRW
Jan 1, 2021
950.16 B KRW
28.75 B KRW
42.94 B KRW
Jan 1, 2022
1.05 T KRW
28.11 B KRW
69.21 B KRW
Jan 1, 2023
1.25 T KRW
57.01 B KRW
115.12 B KRW
Jan 1, 2024
1.28 T KRW
37.96 B KRW
59.42 B KRW

Hanmi Science Co Margins

Hanmi Science Co stock margins

The Hanmi Science Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hanmi Science Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hanmi Science Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
14.05 %
2.14 %
4.61 %
Jan 1, 2018
13.05 %
1.55 %
2.55 %
Jan 1, 2019
13.27 %
1.98 %
3.76 %
Jan 1, 2020
14.08 %
2.93 %
2.64 %
Jan 1, 2021
13.97 %
3.03 %
4.52 %
Jan 1, 2022
15.33 %
2.69 %
6.62 %
Jan 1, 2023
18.88 %
4.57 %
9.23 %
Jan 1, 2024
18.90 %
2.96 %
4.63 %

Hanmi Science Co Stock analysis

What does Hanmi Science Co do? Hanmi Science Co Ltd is a South Korean company specializing in the manufacturing of pharmaceutical products, biologics, and medical devices. The company was founded in 1973 as a chemical company and obtained the license for drug manufacturing in 1990, expanding its product range to include pharmaceuticals. Today, the company's business model includes three main areas: research and development, manufacturing and sales of drugs, and sales of medical devices. Hanmi aims to develop and produce innovative and high-quality products to improve people's health worldwide. In the field of research and development, Hanmi Science is a leading company. It specializes in the research and development of novel drugs and biologics. The company has an impressive track record in the development and marketing of innovative drugs for the treatment of diabetes, cancer, and rare diseases. This includes a range of biosimilars produced using biotechnological methods that are more affordable compared to original medical substances. Hanmi also has a state-of-the-art production infrastructure that meets the highest quality standards and ensures reliable supply. In the field of drug manufacturing, the company produces generics and biosimilars that are sold in more than 50 countries worldwide. Hanmi also specializes in the production of chemotherapeutics and parenteral drugs that have proven efficacy and safety. The medical device sales division focuses on marketing high-quality medical devices, including diagnostic and monitoring devices used in the medical field. Hanmi also distributes a range of medical consumables, including transfusion sets, syringes, infusion sets, and catheters. Hanmi Science Co Ltd offers a wide range of products that can be categorized into various categories. Among the pharmaceutical products are antidiabetic drugs, anticancer agents, antidepressants, antibiotics, antiviral medications, and products for the treatment of rare diseases. The portfolio also includes biosimilars of botulinum toxin, insulin, and humiderm among the biologics. Overall, Hanmi Science Co Ltd holds a strong position in the South Korean market and has also established a good reputation internationally. With its focus on research and development and the production of high-quality drugs and medical devices, the company has a promising future. Hanmi Science Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Hanmi Science Co's EBIT

Hanmi Science Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Hanmi Science Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Hanmi Science Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Hanmi Science Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Hanmi Science Co stock

EBIT of Hanmi Science Co is 37.96 B KRW in 2026.

EBIT of Hanmi Science Co changed from 57.01 B KRW to 37.96 B KRW, representing a -33.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Hanmi Science Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Hanmi Science Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Hanmi Science Co

All Key Metrics — Hanmi Science Co